Table 1.
Demographic and clinical characteristics.
| Measure | SR (n = 12) |
HC (n = 12) |
SR vs. HC1 |
|
|---|---|---|---|---|
| Mean (SD) | Mean (SD) | T-score | p-Value | |
| Age | 32.50 (10.04) | 34.67 (12,25) | −0.474 | 0.640 |
| Sex (m/f) | 4/8 | 4/8 | ||
| PANSS | ||||
| Total | 53.09 (14.56) | 30.41 (1.44) | 5.379 | <0.001* |
| Positive | 12.09 (3.75) | 7.08 (0.29) | 4.824 | <0.001* |
| Negative | 13.08 (5.95) | 7.17 (0.58) | 3.431 | 0.002* |
| General | 27.36 (8.69) | 16.17 (0.58) | 4.458 | <0.001* |
| GAF | 59.09 (15.14) | 99.17 (2.89) | −9.013 | <0.001* |
| CPZ | 207.42 (198.12) | |||
| Duration of illness (years) | 4.11 (3.29) | |||
1Two-sample t-test; *significant for p < 0.05, Bonferroni-corrected for multiple comparisons.
SR, patients with schizophrenia during state of remission; HC, healthy control group; PANSS, Positive and Negative Syndrome Scale; GAF, Global Assessment of Functioning Scale; CPZ, chlorpromazine equivalent dose.